Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $2.15 million. The enterprise value is -$8.89 million.
Important Dates
The last earnings date was Friday, September 12, 2025, before market open.
| Earnings Date | Sep 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 648,313 shares outstanding. The number of shares has increased by 1,007.68% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 648,313 |
| Shares Change (YoY) | +1,007.68% |
| Shares Change (QoQ) | +234.25% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 15.60% |
| Float | 3.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.11 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.03, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.03 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.75 |
Financial Efficiency
Return on equity (ROE) is -64.72% and return on invested capital (ROIC) is -294.85%.
| Return on Equity (ROE) | -64.72% |
| Return on Assets (ROA) | -32.79% |
| Return on Invested Capital (ROIC) | -294.85% |
| Return on Capital Employed (ROCE) | -71.74% |
| Weighted Average Cost of Capital (WACC) | 19.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$660,938 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -141,319 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.24% in the last 52 weeks. The beta is 1.11, so BDRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -96.24% |
| 50-Day Moving Average | 5.45 |
| 200-Day Moving Average | 24.37 |
| Relative Strength Index (RSI) | 36.66 |
| Average Volume (20 Days) | 1,283,534 |
Short Selling Information
The latest short interest is 12,677, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 12,677 |
| Short Previous Month | 42,416 |
| Short % of Shares Out | 1.96% |
| Short % of Float | 0.39% |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | -5.33M |
| Operating Income | -11.64M |
| Pretax Income | -8.73M |
| Net Income | -8.59M |
| EBITDA | -11.57M |
| EBIT | -11.64M |
| Earnings Per Share (EPS) | -$78.31 |
Full Income StatementBalance Sheet
The company has $11.49 million in cash and $82,100 in debt, with a net cash position of $11.40 million or $17.59 per share.
| Cash & Cash Equivalents | 11.49M |
| Total Debt | 82,100 |
| Net Cash | 11.40M |
| Net Cash Per Share | $17.59 |
| Equity (Book Value) | 15.35M |
| Book Value Per Share | 33.99 |
| Working Capital | 8.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.52 million and capital expenditures -$2,692, giving a free cash flow of -$7.41 million.
| Operating Cash Flow | -7.52M |
| Capital Expenditures | -2,692 |
| Depreciation & Amortization | 68,864 |
| Net Borrowing | -921,719 |
| Free Cash Flow | -7.41M |
| FCF Per Share | -$11.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
